Business Description
GlaxoSmithKline Pakistan Ltd
ISIN : PK0001301016
Total Employee Number:
1,606Compare
Compare
Traded in other countries / regions
GLAXO.Pakistan IPO Date
1953-07-03Description
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 27.91 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.5 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.3 | |||||
3-Year EBITDA Growth Rate | 44.6 | |||||
3-Year EPS without NRI Growth Rate | 60.4 | |||||
3-Year Book Growth Rate | 16.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.58 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.87 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.11 | |||||
9-Day RSI | 59.8 | |||||
14-Day RSI | 58.19 | |||||
3-1 Month Momentum % | 12.65 | |||||
6-1 Month Momentum % | -8.98 | |||||
12-1 Month Momentum % | -9.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.43 | |||||
Quick Ratio | 1.59 | |||||
Cash Ratio | 0.62 | |||||
Days Inventory | 125.92 | |||||
Days Sales Outstanding | 8.29 | |||||
Days Payable | 37.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.59 | |||||
Dividend Payout Ratio | 0.46 | |||||
3-Year Dividend Growth Rate | 28.9 | |||||
Forward Dividend Yield % | 4.59 | |||||
5-Year Yield-on-Cost % | 4.67 | |||||
Shareholder Yield % | 4.51 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.78 | |||||
Operating Margin % | 25.07 | |||||
Net Margin % | 15.6 | |||||
EBITDA Margin % | 27.95 | |||||
FCF Margin % | 11.52 | |||||
OCF Margin % | 15.16 | |||||
ROE % | 32.97 | |||||
ROA % | 20.8 | |||||
ROIC % | 29.78 | |||||
3-Year ROIIC % | 64.82 | |||||
ROC (Joel Greenblatt) % | 114.01 | |||||
ROCE % | 51.36 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.03 | |||||
Forward PE Ratio | 10.33 | |||||
PE Ratio without NRI | 11.05 | |||||
Shiller PE Ratio | 23.94 | |||||
Price-to-Owner-Earnings | 11.69 | |||||
PEG Ratio | 0.58 | |||||
PS Ratio | 1.72 | |||||
PB Ratio | 3.2 | |||||
Price-to-Tangible-Book | 3.34 | |||||
Price-to-Free-Cash-Flow | 14.95 | |||||
Price-to-Operating-Cash-Flow | 11.36 | |||||
EV-to-EBIT | 6.23 | |||||
EV-to-EBITDA | 5.75 | |||||
EV-to-Revenue | 1.61 | |||||
EV-to-FCF | 13.83 | |||||
Price-to-GF-Value | 1.14 | |||||
Price-to-Projected-FCF | 2.03 | |||||
Price-to-DCF (Earnings Based) | 0.85 | |||||
Price-to-DCF (FCF Based) | 1.32 | |||||
Price-to-Median-PS-Value | 1.16 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.54 | |||||
Price-to-Graham-Number | 1.29 | |||||
| Price-to-Net-Current-Asset-Value | 5.67 | |||||
Earnings Yield (Greenblatt) % | 16.05 | |||||
FCF Yield % | 6.58 | |||||
Forward Rate of Return (Yacktman) % | 21.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GlaxoSmithKline Pakistan Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₨) | 67,349.086 | ||
| EPS (TTM) (₨) | 33.009 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 1.23 | ||
| 3-Year Sortino Ratio | 2.89 | ||
| Volatility % | 31.58 | ||
| 14-Day RSI | 58.19 | ||
| 14-Day ATR (₨) | 7.919834 | ||
| 20-Day SMA (₨) | 361.641 | ||
| 12-1 Month Momentum % | -9.2 | ||
| 52-Week Range (₨) | 293.09 - 459.27 | ||
| Shares Outstanding (Mil) | 318.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GlaxoSmithKline Pakistan Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GlaxoSmithKline Pakistan Ltd Stock Events
| Event | Date | Price (₨) | ||
|---|---|---|---|---|
| PKR 12.000000 Cash Dividend | 2026-04-24 | 382.32 (-0.69%) | ||
| PKR 5.000000 Cash Dividend | 2025-09-05 | 414.81 (-0.29%) | ||
| PKR 10.000000 Cash Dividend | 2025-04-18 | 455.87 (+1.79%) | ||
| 1.1:1 Stock Split | 2014-04-18 | 145.68 (-3.56%) | ||
| 1.1:1 Stock Split | 2013-04-11 | 61.04 (+0.27%) | ||
| 1.1:1 Stock Split | 2012-03-29 | 46.98 (-0.32%) | ||
| 1.15:1 Stock Split | 2011-04-12 | 50.34 (-0.69%) |
Show
Entries
GlaxoSmithKline Pakistan Ltd Frequently Asked Questions
What is GlaxoSmithKline Pakistan Ltd(KAR:GLAXO)'s stock price today?
The current price of KAR:GLAXO is ₨370.25. The 52 week high of KAR:GLAXO is ₨459.27 and 52 week low is ₨293.09.
When is next earnings date of GlaxoSmithKline Pakistan Ltd(KAR:GLAXO)?
The next earnings date of GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) is .
Does GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) pay dividends? If so, how much?
The Dividend Yield %  of GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) is 4.59% (As of Today), Highest Dividend Payout Ratio of GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) was 0.95. The lowest was 0.4. And the median was 0.54. The  Forward Dividend Yield % of GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) is 4.59%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on GlaxoSmithKline Pakistan Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers